Skip to main content

Table 1 Unit costs (EUR 2019)

From: Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway

Type Sweden Norway
Cost (EUR) Source Cost (EUR) Source
Treatments
 Botox (PSP) 347 [29] 335 [30]
 Placebo
Administration
 Neurology consultant appointment 279 [31] 248 [32]
 Specialist nurse appointment 86 [33] 50 [34]
Resources
 GP appointment 155 [31] 33 [35]
 A&E visit 279 [31] 73 [35]
 Hospitalisation (per day) 665 [31] 771 [32]
 Cost of triptans (per attack) 2 [29] 4 [36]
Productivity
 Average hourly wage 40 [37, 38] 45 [34]
Additional inputs used in COI analyses
 Value of spare time/hour 11 [39]
 Value of spare time, retail price/hour 22 [40, 41]
 GP appointment (acute) 369 [31]
  1. Key: A&E Accident and emergency; GP General practitioner; PSP Pharmacy selling price; VAT Value added tax
  2. Note: In Norway the VAT for pharmaceuticals is 25%, while there is no VAT for prescription pharmaceuticals in Sweden. The analyses were undertaken excluding VAT. All Swedish unit costs except average wage are sourced from 2019. Average wage was inflated from 2018 to 2019 values using CPI from Statistics Sweden [42]. Some of the Norwegian unit costs have been inflated to 2019 values using CPI from Statistics Norway [43]. All costs are presented in EUR, using ECB average annual 2019 NOK/EUR and SEK/EUR exchange rates [44, 45]